Ionis Pharmaceuticals IONS Adjustments To Additional Paid In Capital Inducement Related To Repurchase Of Convertible Senior Notes
Adjustments To Additional Paid In Capital Inducement Related To Repurchase Of Convertible Senior Notes at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:AdjustmentsToAdditionalPaidInCapitalInducementRelatedToRepurchaseOfConvertibleSeniorNotes.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's adjustments to additional paid in capital inducement related to repurchase of convertible senior notes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's adjustments to additional paid in capital inducement related to repurchase of convertible senior notes?
- Ionis Pharmaceuticals (IONS) reported adjustments to additional paid in capital inducement related to repurchase of convertible senior notes of $12.92M in Q4 2025.
- What does adjustments to additional paid in capital inducement related to repurchase of convertible senior notes mean?
- Equity adjustments made when the company pays to induce debt holders to convert their debt into stock.
- How do you interpret adjustments to additional paid in capital inducement related to repurchase of convertible senior notes?
- An increase indicates active management of the capital structure to reduce debt obligations, potentially improving the balance sheet at the cost of equity dilution.
- How does adjustments to additional paid in capital inducement related to repurchase of convertible senior notes compare across companies?
- Standard for companies managing complex capital structures involving convertible notes.